The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Telehealth psychiatry, therapy apps, AI mental health, digital therapeutics.
No regulator currently certifies whether an AI chatbot is safe to use for mental health support. NAMI's expanded partnership with digital psychiatry researcher John Torous, and the live MindBench.ai platform it has already produced, is building that evaluation infrastructure directly, ahead of any formal regulatory framework.
The real-world-evidence platform behind more than a thousand independent psychiatry practices administering ketamine and esketamine today has signed a multi-year deal to help Tasman Therapeutics design its Phase 3 trial and build its future commercialization infrastructure. Nothing about the deal is improper. It does mark a new kind of player entering psychedelic-adjacent drug development, one whose core asset is neutrality, now becoming financially interested in a single company's outcome.
A targeting trial in TMS, a statistical test built for a tDCS headset, and an autonomic-biomarker study in deep brain stimulation have nothing to do with each other on paper. Read together, they describe the same shift happening in parallel across neuromodulation's major device categories: away from asking whether a device works in aggregate, and toward asking for whom, through what mechanism, and how confidently anyone can tell the difference between a real effect and a confound.
A retrospective analysis of 3,041 Mindbloom patients reports high rates of clinical improvement from at-home subcutaneous ketamine, a genuinely under-studied delivery route. The topline numbers are real. So is the conflict of interest, the near-total attrition by the final assessment, and the gap between the headline improvement rate and the much lower remission rate underneath it.
Every neuromodulation and psychedelic trial this desk covers eventually runs into the same problem: patients can often tell whether they got the real treatment. A new analysis of a home-use tDCS depression trial does something most studies don't bother with, it empirically tests whether that broken blind actually distorted the outcome, rather than treating unblinding and bias as the same thing.
Researchers have systematically catalogued clinics using direct-to-consumer advertising to sell off-label ketamine in the New York metro area, the densest such market yet studied. A comparable study elsewhere found extensive misrepresentation of the drug's approval status and risks. The empirical baseline now exists. What regulators do with it is the open question.
SAMHSA has opened a comment period on building an independent accreditation system for the federal Certified Community Behavioral Health Clinic expansion program, a 500-clinic, now-permanent Medicaid benefit. The design choices being written now, who accredits, what the standards are, and whether failing costs grant money, will set the operating economics for a large slice of the behavioral-health-services sector.
A JAMA Psychiatry randomized trial found that aiming accelerated TMS with individual brain imaging beat the standard scalp-landmark method, an 80 percent response rate against 60. It is the strongest evidence yet that the personalized approach earns its cost, which pushes the fastest-growing depression neuromodulation toward precision, expense, and the imaging-capable centers that can deliver it.
Vagus nerve stimulation, deep brain stimulation, and now non-invasive temporal interference form a device-based axis of behavioral health that gets covered one gadget at a time, never as a category. Seen whole, it shares a single obstacle: proving itself against a sham.
The Oversight of Artificial Intelligence Technology in Mental Health Care Act, H7349, was signed on June 22, 2026, after clearing the House in substitute form. Rhode Island is among the first states to govern clinical AI in mental health rather than ban it, and the enacted text now sets the scope and enforcement.
One law governs AI used in clinical treatment. Another sets safety rules for companion chatbots. Signed together on June 22, 2026, they form a govern-it model other states are watching as the alternative to an outright ban.
CMS's January 2025 creation of three Medicare reimbursement codes for digital mental health treatment is the most consequential thing that has happened to the prescription digital therapeutics market since the FDA started clearing them. The codes' narrow scope is doing more to shape the field than the clearances themselves.
Hims and Hers, the category's public bellwether, grew 4 percent last quarter and swung to a loss. The growth now comes from branded weight-loss drugs and overseas expansion. Mental health is one specialty on a platform that has stopped being about mental health.
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| CT-155 Schizophrenia (negative symptoms) | Click Therapeutics (Boehringer Ingelheim) | Phase 3 | CONVOKE Phase 3 positive; commercialization transferred to Click |
| Rejoyn Major depressive disorder (adjunct) | Otsuka / Click Therapeutics | Approved | First FDA-cleared MDD app |
| Sleepio / Daylight Insomnia and anxiety | Big Health | Approved | Marketed digital therapeutics |